GS 9137 (elvitegravir)

el-vy-TEH-gra-veer



Drug Class: Integrase Inhibitors

GS 9137 is a type of medicine called an integrase inhibitor. Integrase inhibitors work by blocking integrase, a protein that HIV needs to insert its viral genetic material into the genetic material of an infected cell.

HIV/AIDS-Related Uses

GS 9137 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the treatment of HIV infection. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Dosage Form/Administration

GS 9137 is taken by mouth with food.

Recommended Daily Dose

Many dosages of GS 9137 have been studied. Once-daily dosages of 25, 50, and 125 mg will continue to be studied; all of these doses will be given by mouth with ritonavir 100 mg.

Contraindications

Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects

Along with its desired effects, GS 9137 may cause some unwanted effects. Although not all of these effects are known, headache, loss of appetite, and elevated liver enzyme levels have been reported.

Drug and Food Interactions

A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials

For information on clinical trials that involve GS 9137 (elvitegravir), visit the ClinicalTrials.gov web site at http://www.clinicaltrials.gov. In the Search box, enter: GS 9137 (elvitegravir) AND HIV Infections.

Manufacturer Information

GS 9137 (elvitegravir) Gilead Sciences Inc 333 Lakeside Dr Foster City, CA 94404 (800) 445-3235

For More Information

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday Friday, 12:00 p.m. (Noon) 5:00 p.m. ET
- Via Live Help: http://aidsinfo.nih.gov/live_help Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET